Is ADMA a Buy or a Sell? The Bull and Bear Case (2026)

That depends on which case you find more convincing, and both are on this page. The bull case rests on Asceniv, the specialty growth driver, with revenue (ttm) at ~$512 million. The bear case rests on the dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue in Q1 2026 and led ADMA to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. Analysts covering it are spread from $12.00 to $21.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.

Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. The dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue in Q1 2026 and led ADMA to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $12.00, +12.4% from the $10.68 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.

Asceniv, the specialty growth driver. Asceniv, ADMA's differentiated immune globulin for primary immunodeficiency, is the company's main growth engine, with revenue up about 28% in Q1 2026 even as total revenue stayed flat. The most optimistic analyst target on ADMA is $21.00, +96.6% from the $10.68 price. That figure is only reachable if this thesis works close to its best case.

The dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue in Q1 2026 and led ADMA to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics. Elevated channel inventories can delay a recovery in standard-IG sales. Concentration risk is real: growth now leans heavily on a single specialty product, Asceniv, so any stumble there would weigh disproportionately. Plasma-derived manufacturing depends on collecting enough specialized plasma and on regulatory compliance, and thrombosis remains a labeled risk for all IVIG products, including Asceniv and Bivigam. Free cash flow is thin relative to earnings (about $55 million trailing) and the company carries about $204 million of debt against $136 million of cash. As a relatively small biopharma, ADMA is more exposed to single-product and single-market shocks than a diversified drugmaker, and its shares have been volatile, trading between $7.21 and $20.46 over the past year. Larger, better-resourced plasma competitors can sustain price competition longer than ADMA. The most pessimistic published target is $12.00, +12.4% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.

ADMA Biologics is an end-to-end biopharmaceutical company focused on plasma-derived therapies.

Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Asceniv, the specialty growth driver) stalling in the reported numbers rather than in the narrative, the risk above (the dominant near-term risk is competition and pricing pressure in the standard immunoglobulin market, which drove a 54% drop in Bivigam revenue in Q1 2026 and led ADMA to cut full-year guidance, reduce its net-income outlook, and withdraw long-term targets, citing rapidly evolving competitive dynamics) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice; Walnut is not an investment adviser. The bull case is a fast-growing specialty product in Asceniv, an integrated plasma model, consistent profitability, and a valuation near 11x forward earnings after a 40% fall in 2026. The bear case is that ADMA cut 2026 guidance, withdrew long-term targets, and faces heavy pricing competition in standard IG, with growth now concentrated in one product. Weigh both against your portfolio and your tolerance for a volatile small-cap biopharma.

ADMA develops, manufactures, and markets plasma-derived immunoglobulin products that treat immune deficiencies and help prevent certain infections, and it operates its own plasma-collection centers. Its FDA-approved products are Asceniv, its differentiated specialty immune globulin, Bivigam, a standard intravenous immune globulin, and Nabi-HB for hepatitis B exposure. It is a vertically integrated plasma-products company.

ADMA lowered its full-year 2026 revenue and net-income outlook and withdrew long-term targets because of increased competition, elevated channel inventories, and aggressive pricing in the standard immunoglobulin market, which hurt Bivigam sales. It revised revenue guidance to roughly $530 to $560 million from a prior view above $635 million. The company cited rapidly evolving competitive dynamics.